Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma

NCT03572582 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Hepatocellular
Hepatic Carcinoma
Hepatocellular Cancer

Interventions

DRUG: Nivolumab
DRUG: TACE

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]